Hemab Therapeutics Holdings, Inc. (NasdaqGS: COAG)
Salud · Biotecnología · US
39,06 $
+0,01 % hoy · +14,9 % 1 año
Hemab Therapeutics Holdings, Inc. (NasdaqGS: COAG) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 1,83 mil M $ y tiene 59 empleados.
En los últimos doce meses la acción ha subido un 14,9 % y ha cotizado entre 23,00 y 55,42.
Tweenvest puntúa a Hemab Therapeutics Holdings, Inc. en cuatro factores: calidad 46/100, valor 100/100. Su punto más fuerte es valor.
Evolución de la cotización de COAG
Cifras clave
- Capitalización
- 1,83 mil M $
- Ingresos (últ. 12 m)
- —
- PER
- -37,48
- BPA
- -67,56
- Rent. por dividendo
- —
- Beta (5 años)
- —
- Máximo 52 semanas
- 55,42 $
- Mínimo 52 semanas
- 23,00 $
- Volumen medio (3 m)
- —
- Acciones en circulación
- 46,73 M
- Empleados
- 59
- Próximos resultados
- —
Sobre Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
- ISIN
- US4234941031
- Fundada en
- 2020
- Cotiza desde
- 1 may 2026
- Bolsa
- Nasdaq Global Select
- Divisa
- USD
Otras empresas de biotecnología
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| Anhui Anke Biotechnology (Group) Co., Ltd.SZSE: 300009 | 1,89 mil M $ | 7,56 CN¥ | -0,92 % |
| BioCryst Pharmaceuticals, Inc.NasdaqGS: BCRX | 1,88 mil M $ | 7,30 $ | -2,67 % |
| Replimune Group, Inc.NasdaqGS: REPL | 1,88 mil M $ | 19,81 $ | +0,61 % |
| Zenas BioPharma, Inc.NasdaqGS: ZBIO | 1,87 mil M $ | 27,64 $ | -3,69 % |
| Genus plcLSE: GNS | 1,82 mil M $ | 21,56 £ | -4,52 % |
| Sino Biological,Inc.SZSE: 301047 | 1,81 mil M $ | 99,20 CN¥ | -11,02 % |
| Ultragenyx Pharmaceutical Inc.NasdaqGS: RARE | 1,80 mil M $ | 17,73 $ | +6,23 % |
| Zymeworks Inc.NasdaqGS: ZYME | 1,80 mil M $ | 26,04 $ | +0,81 % |